Equities Analysts Issue Forecasts for Milestone Pharmaceuticals Inc.’s FY2027 Earnings (NASDAQ:MIST)

Milestone Pharmaceuticals Inc. (NASDAQ:MIST – Get Rating) – Investment analysts at HC Wainwright issued their FY2027 EPS estimates for Milestone Pharmaceuticals in a research report issued to clients and investors on Thursday, March 9th. HC Wainwright analyst P. Trucchio anticipates that the company will post earnings per share of $2.18 for the year. HC Wainwright has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for Milestone Pharmaceuticals’ current full-year earnings is ($1.43) per share.

Milestone Pharmaceuticals Price Performance

Shares of NASDAQ:MIST opened at $3.20 on Friday. The company’s fifty day moving average price is $3.70 and its 200-day moving average price is $5.39. The firm has a market capitalization of $109.73 million, a price-to-earnings ratio of -2.19 and a beta of 1.99. Milestone Pharmaceuticals has a one year low of $3.11 and a one year high of $9.85.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in MIST. JPMorgan Chase & Co. boosted its holdings in shares of Milestone Pharmaceuticals by 94.7% in the 1st quarter. JPMorgan Chase & Co. now owns 13,580 shares of the company’s stock worth $87,000 after purchasing an additional 6,606 shares in the last quarter. Acadian Asset Management LLC lifted its position in Milestone Pharmaceuticals by 55.6% in the 1st quarter. Acadian Asset Management LLC now owns 19,270 shares of the company’s stock worth $122,000 after buying an additional 6,889 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in Milestone Pharmaceuticals by 17.4% in the first quarter. Dimensional Fund Advisors LP now owns 61,743 shares of the company’s stock worth $397,000 after buying an additional 9,165 shares in the last quarter. PDT Partners LLC bought a new position in Milestone Pharmaceuticals during the first quarter valued at approximately $65,000. Finally, BNP Paribas Arbitrage SA bought a new stake in Milestone Pharmaceuticals in the first quarter worth $25,000. 73.84% of the stock is currently owned by hedge funds and other institutional investors.

Milestone Pharmaceuticals Company Profile

(Get Rating)

Milestone Pharmaceuticals, Inc engages in the development and commercialization of cardiovascular medicines. Its lead product candidate etripamil, is a novel, potent and short-acting calcium channel blocker that is designed as a rapid-onset nasal spray to be self-administered by patients. It develops etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, rapid ventricular rate, and other cardiovascular indications.